Regeneron Q2 2026 EPS USD 14.29 beats estimate of USD 10.3; revenue USD 4,291M beats USD 3,816M estimate; Dupixent global net sales up 38% to USD 6B; EYLEA HD US net sales up 52% to USD 596M.
LiveSquawk07/30, 05:44 PM
Related assets
Coming up for REGN
Explore next
Latest REGN news
Bloomberg07/31, 06:40 PM
FirstSquawk07/31, 12:37 PM
JPMorgan raised Regeneron Pharmaceuticals price target to $900 from $850.
ZeroHedge07/30, 06:54 PM